Slide 1: Q2 FY2026 Presentation of Second Quarter Results
Q2 FY2026 Presentation of Second Quarter Results ASX:BXN January 2026
Slide 2: Disclaimer
Disclaimer This presentation (Presentation) has been prepared by Bioxyne Limited ABN 97 084 464 193 (Bioxyne or the Company). The information in this Presentation is of a general background nature, is in summary form and does not purport to be complete. The information in this presentation is subjec
Slide 3: Redefining Medicine
Redefining Medicine Cannabis | Psilocybin | MDMA World’s Fastest Growing Pharmaceutical Manufacturer for patients with unmet clinical needs
Slide 4: What we do
What we do Bioxyne is a multinational pharmaceutical manufacturer and healthcare company. Wholly owned subsidiary Breathe Life Sciences is becoming a global market-leading distributor of controlled drugs, active pharmaceutical ingredients, and final does form medicines derived from cannabis, MDMA, P
Slide 5: Q2FY26 Overview - Another Record Quarter
Q2FY26 Overview - Another Record Quarter Record $17.2m Revenue Record $18.4m Cash $2.5m Positive Cash Flow $7.6m Cash on Hand Receipts from Operations +21% QoQ Inc. $1.6m non-dilutive $0.7m Capex loan/grant funding from +112% on PcP Scottish Gov. Entry into New Markets: Contract wins with First Aust
Slide 6: Sustained Growth +112% LTM
Sustained Growth +112% LTM BXN REVENUE BY QUARTER ($m) $17.2m Key drivers of growth • Expanded Australian manufacturing capacity $14.0m • Strong increase in white-label and branded product sales • Successful entry into Germany and UK markets $9.6m • Significant contribution from export orders $8.0m
Slide 7: Cash Flow Positive & $7.6m Cash on Hand
Cash Flow Positive & $7.6m Cash on Hand CASH RECEIPTS & NET CASH USED IN OPERATING ACTIVITIES ($m) $18.4m Record cash receipts of $18.4 million 149% increase vs prior corresponding period (PCP) and 43% up on prior quarter (QoQ) $12.9m $10.7m Positive operating cash flow of $2.5 million in $6.8m $7.4
Slide 8: Operational & Strategic Wins
Operational & Strategic Wins • Exclusive Manufacturing Agreement for Curaleaf QMID medical device. NEW PARTNERSHIPS DRIVING • Remidose agreement for THC pastilles in Costa Rica & Panama; (first-mover and GROWTH ~A$1 million potential revenue p.a. FAST-MOVING IN EUROPE'S • Secured £850k (~A$1.6M) gov
Slide 9: Corporate Structure
Corporate Structure CAPITAL STRUCTURE FY26 GUIDANCE Share price $0.039 Revenue $65m to $75m Market capitalisation $86.79m EBITDA $11.5 to $13.5m 52-week high $0.060 52-week low $0.019 31% $0.06 60m Directors Other 69% $0.04 40m Share price $0.02 20m 30% Top 20 - - Other 70% Volume Share Price BXN Sh